Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion : Insight from an international STEMI registry

Autor: Lisette Okkels Jensen, Gianni Casella, Vladimir Ganyukov, José Moreu, Stephane Manzo, Giuseppe De Luca, Elvin Kedhi, Juan Sanchis Forés, Alejandro Gutierrez Barrios, Raul Moreno, Adriaan O. Kraaijeveld, Mika Laine, Xavier Carrillo, Nikola Bakraceski, Montserrat Gracida Blancas, Giuseppe Uccello, Michał Kidawa, Miha Cercek, Gabriele Gabrielli, Andrea Santucci, Maurizio Menichelli, Iñigo Lozano Martínez-Luengas, Giuliana Cortese, Gianluca Caiazzo, Pierfrancesco Agostoni, Benjamin Faurie, Dimitrios Alexopulos, Bruno Scheller, Monica Verdoia, Giovanni Amoroso, Sébastien Levesque, Xacobe Flores Rios, Lucian Calmac, Wojtek Wojakowski, Lucia Marinucci, Periklis Davlouros, Petr Kala, Heidi Lehtola, Gennaro Galasso, Vincenzo Guiducci, Bor Wilbert, Tomas Kovarnik, Thomas W Johnson, Gabriella Visconti, Victor Becerra, Luca Donazzan, Filippo Zilio, Francisco Bosa Ojeda, Jurriën M. ten Berg, Bernabé López Ledesma, Arpad Lux, Tim Berkout, Luigi Vignali, Alessandra Scoccia, Enrico Fabris, Rui Campante Teles, Maurits T. Dirksen, Oliver Bushljetikj, Roberto Padalino, Alexander Ijsselmuiden, Guido Parodi, Santiago Camacho-Freiere, Francesco Versaci, Ylitalo Antti, Fortunato Scotto Di Uccio, Bernardo Tuccillo, Clemens von Birgelen
Přispěvatelé: HUS Abdominal Center, Kardiologian yksikkö
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Male
medicine.medical_treatment
THERAPY
Percutaneous coronary intervention
Renin-Angiotensin System
0302 clinical medicine
Pandemic
Renin-Angiotensin System inhibitors
Myocardial infarction
Registries
education.field_of_study
General Medicine
Middle Aged
Prognosis
3. Good health
Hospitalization
WUHAN
317 Pharmacy
030220 oncology & carcinogenesis
Original Article
Female
Lower mortality
RECEPTOR BLOCKERS
medicine.medical_specialty
Coronavirus disease 2019 (COVID-19)
Population
Myocardial Reperfusion
RM1-950
CHINA
03 medical and health sciences
MORBIDITY
LEFT-VENTRICULAR DYSFUNCTION
Internal medicine
Renin–angiotensin system
medicine
Mortalitat
Humans
In patient
Mortality
education
Pandemics
Antihypertensive Agents
Aged
Pharmacology
business.industry
SARS-CoV-2
COVID-19
medicine.disease
COVID-19 Drug Treatment
ST-segment elevation myocardial infarction
030104 developmental biology
MYOCARDIAL-INFARCTION
Percutaneous Coronary Intervention
ST Elevation Myocardial Infarction
Therapeutics. Pharmacology
3111 Biomedicine
business
Zdroj: Dipòsit Digital de la UB
Universidad de Barcelona
Biomedicine & Pharmacotherapy
De Luca, G, Cercek, M, Okkels Jensen, L, Bushljetikj, O, Calmac, L, Johnson, T, Gracida Blancas, M, Ganyukov, V, Wojakowski, W, von Birgelen, C, IJsselmuiden, A, Tuccillo, B, Versaci, F, Ten Berg, J, Laine, M, Berkout, T, Casella, G, Kala, P, López Ledesma, B, Becerra, V, Padalino, R, Santucci, A, Carrillo, X, Scoccia, A, Amoroso, G, Lux, A, Kovarnik, T, Davlouros, P, Gabrielli, G, Flores Rios, X, Bakraceski, N, Levesque, S, Guiducci, V, Kidawa, M, Marinucci, L, Zilio, F, Galasso, G, Fabris, E, Menichelli, M, Manzo, S, Caiazzo, G, Moreu, J, Sanchis Forés, J, Donazzan, L, Vignali, L, Teles, R, Agostoni, P, Bosa Ojeda, F, Lehtola, H, Camacho-Freiere, S, Kraaijeveld, A, Antti, Y, Visconti, G, Lozano Martínez-Luengas, I, Scheller, B, Alexopulos, D, Moreno, R, Kedhi, E, Uccello, G, Faurie, B, Gutierrez Barrios, A, Scotto Di Uccio, F, Wilbert, B, Cortese, G, Dirksen, M T, Parodi, G & Verdoia, M 2021, ' Impact of renin-angiotensin system inhibitors on mortality during the COVID Pandemic among STEMI patients undergoing mechanical reperfusion : Insight from an international STEMI registry ', Biomedicine and Pharmacotherapy, vol. 138, 111469 . https://doi.org/10.1016/j.biopha.2021.111469
Biomedicine & Pharmacotherapy, Vol 138, Iss, Pp 111469-(2021)
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
ISSN: 1950-6007
DOI: 10.1016/j.biopha.2021.111469
Popis: Background: Concerns have been raised on a potential interaction between renin-angiotensin system inhibitors (RASI) and the susceptibility to coronavirus disease 2019 (COVID-19). No data have been so far reported on the prognostic impact of RASI in patients suffering from ST-elevation myocardial infarction (STEMI) during COVID-19 pandemic, which was the aim of the present study. Methods: STEMI patients treated with primary percutaneous coronary intervention (PPCI) and enrolled in the ISACS-STEMI COVID-19 registry were included in the present sub-analysis and divided according to RASI therapy at admission. Results: Our population is represented by 6095 patients, of whom 3654 admitted in 2019 and 2441 in 2020. No difference in the prevalence of SARSCoV2 infection was observed according to RASI therapy at admission (2.5% vs 2.1%, p = 0.5), which was associated with a significantly lower mortality (adjusted OR [95% CI]=0.68 [0.51 & ndash;0.90], P = 0.006), confirmed in the analysis restricted to 2020 (adjusted OR [95% CI]=0.5[0.33 & ndash;0.74], P = 0.001). Among the 5388 patients in whom data on in-hospital medication were available, in-hospital RASI therapy was associated with a significantly lower mortality (2.1% vs 16.7%, OR [95% CI]=0.11 [0.084 & ndash;0.14], p < 0.0001), confirmed after adjustment in both periods. Among the 62 SARSCoV-2 positive patients, RASI therapy, both at admission or in-hospital, showed no prognostic effect. Conclusions: This is the first study to investigate the impact of RASI therapy on the prognosis and SARSCoV2 infection of STEMI patients undergoing PPCI during the COVID-19 pandemic. Both pre-admission and in-hospital RASI were associated with lower mortality. Among SARSCoV2-positive patients, both chronic and in-hospital RASI therapy showed no impact on survival.
Databáze: OpenAIRE
Externí odkaz: